1,295 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors http://www.zacks.com/stock/news/431013/roches-rozlytrek-gets-approval-in-japan-for-solid-tumors?cid=CS-ZC-FT-431013 Jun 18, 2019 - Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz http://www.zacks.com/stock/news/430687/novartis-nvs-announces-promising-data-on-tasigna-hyrimoz?cid=CS-ZC-FT-430687 Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris http://www.zacks.com/stock/news/429338/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris?cid=CS-ZC-FT-429338 Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Top Analyst Reports for Visa, Netflix & Accenture http://www.zacks.com/research-daily/429094/top-analyst-reports-for-visa-netflix-accenture?cid=CS-ZC-FT-429094 Jun 13, 2019 - Top Analyst Reports for Visa, Netflix & Accenture
Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $15.9 million of Shares http://www.gurufocus.com/news/893420/elastic-nv-estc-ceo-and-chairman-shay-banon-sold-159-million-of-shares Jun 12, 2019 - Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $15.9 million of Shares, Stocks: ESTC, release date:Jun 12, 2019
Roche's Rituxan Gets Priority Review for Blood Disorder http://www.zacks.com/stock/news/428757/roches-rituxan-gets-priority-review-for-blood-disorder?cid=CS-ZC-FT-428757 Jun 12, 2019 - Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis http://www.zacks.com/stock/news/428752/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis?cid=CS-ZC-FT-428752 Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399 Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
Roche Receives FTC Request for Further Data on Spark Buyout http://www.zacks.com/stock/news/427145/roche-receives-ftc-request-for-further-data-on-spark-buyout?cid=CS-ZC-FT-427145 Jun 10, 2019 - Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
Celgene's Filing for Ozanimod Accepted for Review in US/EU http://www.zacks.com/stock/news/426482/celgenes-filing-for-ozanimod-accepted-for-review-in-us-eu?cid=CS-ZC-FT-426482 Jun 07, 2019 - The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Pages: 12345678...130

<<<Page 3>